Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Döhner, Hartmut; Wei, Andrew H.; Appelbaum, Frederick R.; Craddock, Charles; DiNardo, Courtney D.; Dombret, Hervé; Ebert, Benjamin L.; Fenaux, Pierre; Godley, Lucy A.; Hasserjian, Robert P.; Larson, Richard A.; Levine, Ross L.; Miyazaki, Yasushi; Niederwieser, Dietger; Ossenkoppele, Gert J.; Röllig, Christoph; Sierra, Jorge; Stein, Eytan M.; Tallman, Martin S.; Tien, Hwei‐Fang; Wang, Jianxiang; Wierzbowska, Agnieszka; Löwenberg, Bob

doi:10.1182/blood.2022016867

articleBloodJul 7, 2022BRONZE OA

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

HDHartmut Döhner AHAndrew H. Wei FRFrederick R. Appelbaum CCCharles Craddock CDCourtney D. DiNardo

University Hospital Ulm · The Royal Melbourne Hospital · +25 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment…

Citation impact

2,936

total citations

FWCI: 417.70
Percentile: 100%
References: 207

Citations per year

Authors

23

Topics & keywords

Topics

Keywords

Medicine
Intensive care medicine
Myeloid leukemia
Disease
IDH2
Molecular diagnostics
IDH1
Bioinformatics

No related works found for this paper.